Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 3/2020

02.07.2019

The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS)

verfasst von: Alison Haley Kucharik, Christopher Chang

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

In recent years, an association between hypermobile Ehlers-Danlos syndrome (hEDS), mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS) has garnered attention and patients are increasingly presenting with this triad. However, a real relationship between these entities is unclear due to a lack of scientific validity. We conducted an extensive review of the literature using two different search strategies. A narrower strategy included 88 searches of various combinations of terms for each of the three conditions, yielding 19 unique papers. A broader search included 136 searches of various combinations of terms but included all forms of EDS and yielded 40 unique papers. Of these, only four and nine papers from the narrower and broader search strategies were original research articles. None of these papers resulted from a combination of the search terms for the three conditions. All three clinical entities are controversial in either existence or pathogenesis. MCAS is a poorly defined clinical entity, and many studies do not adhere to the proposed criteria when establishing the diagnosis. Patients previously diagnosed with EDS hypermobility type may not meet the new, stricter criteria for hEDS but may for a less severe hypermobility spectrum disorder (HSD). The pathophysiology of POTS is still unclear. An evidence-based, common pathophysiologic mechanism between any of the two, much less all three conditions, has yet to be described. Our review of the literature shows that current evidence is lacking on the existence of MCAS or hEDS as separate or significant clinical entities. Studies proposing a relationship between the three clinical entities are either biased or based on outdated criteria. The reason behind the purported association of these entities stems from an overlapping pool of vague, subjective symptoms, which is inadequate evidence to conclude that any such relationship exists.
Literatur
1.
Zurück zum Zitat Beighton P, Grahame R, Bird H (2012) Introduction to hypermobility. In: Hypermobility of joints. Springer, p 1 Beighton P, Grahame R, Bird H (2012) Introduction to hypermobility. In: Hypermobility of joints. Springer, p 1
2.
Zurück zum Zitat Parapia LA, Jackson C (2008) Ehlers-Danlos syndrome – a historical review. Br J Haematol. 141(1):32–35PubMedCrossRef Parapia LA, Jackson C (2008) Ehlers-Danlos syndrome – a historical review. Br J Haematol. 141(1):32–35PubMedCrossRef
3.
Zurück zum Zitat Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ (1999) Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Am J Med Genet. 77(1):31–37CrossRef Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ (1999) Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Am J Med Genet. 77(1):31–37CrossRef
4.
Zurück zum Zitat Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J et al (2017) The 2017 International Classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):8–26PubMedCrossRef Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J et al (2017) The 2017 International Classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):8–26PubMedCrossRef
5.
Zurück zum Zitat Steinmann B, Royce PM, Superti-Furga A (2003) The Ehlers-Danlos syndrome. In: Connective tissue and its heritable disorders. Wiley-Blackwell, pp 431–523 Steinmann B, Royce PM, Superti-Furga A (2003) The Ehlers-Danlos syndrome. In: Connective tissue and its heritable disorders. Wiley-Blackwell, pp 431–523
6.
Zurück zum Zitat Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kazkaz H et al (2017) Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome type III and Ehlers–Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet. 175(1):48–69PubMedCrossRef Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kazkaz H et al (2017) Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome type III and Ehlers–Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet. 175(1):48–69PubMedCrossRef
7.
Zurück zum Zitat De Paepe A, Malfait F (2012) The Ehlers–Danlos syndrome, a disorder with many faces. Clin Genet. 82(1):1–11PubMedCrossRef De Paepe A, Malfait F (2012) The Ehlers–Danlos syndrome, a disorder with many faces. Clin Genet. 82(1):1–11PubMedCrossRef
8.
Zurück zum Zitat Castori M, Camerota F, Celletti C, Grammatico P, Padua L (2010) Ehlers-Danlos syndrome hypermobility type and the excess of affected females: possible mechanisms and perspectives. Am J Med Genet A. 152A(9):2406–2408PubMedCrossRef Castori M, Camerota F, Celletti C, Grammatico P, Padua L (2010) Ehlers-Danlos syndrome hypermobility type and the excess of affected females: possible mechanisms and perspectives. Am J Med Genet A. 152A(9):2406–2408PubMedCrossRef
9.
Zurück zum Zitat Levy HP (2018) Ehlers-Danlos syndrome, hypermobility type. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K et al (eds) GeneReviews. University of Washington, Seattle, Seattle Levy HP (2018) Ehlers-Danlos syndrome, hypermobility type. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K et al (eds) GeneReviews. University of Washington, Seattle, Seattle
10.
Zurück zum Zitat Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, Otero M et al (2003) Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. Am J Hum Genet. 73(1):214–217PubMedPubMedCentralCrossRef Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, Otero M et al (2003) Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. Am J Hum Genet. 73(1):214–217PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Morissette R, Chen W, Perritt AF, Dreiling JL, Arai AE, Sachdev V et al (2015) Broadening the spectrum of Ehlers Danlos syndrome in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 100(8):1143CrossRef Morissette R, Chen W, Perritt AF, Dreiling JL, Arai AE, Sachdev V et al (2015) Broadening the spectrum of Ehlers Danlos syndrome in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 100(8):1143CrossRef
12.
Zurück zum Zitat Narcisi P, Richards AJ, Ferguson SD, Pope FM (1994) A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen. Hum Mol Genet. 3(9):1617–1620PubMedCrossRef Narcisi P, Richards AJ, Ferguson SD, Pope FM (1994) A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen. Hum Mol Genet. 3(9):1617–1620PubMedCrossRef
13.
Zurück zum Zitat Syx D, Symoens S, Steyaert W, De Paepe A, Coucke PJ, Malfait F (2015) Ehlers-Danlos syndrome, hypermobility type, is linked to chromosome 8p22-8p21.1 in an extended Belgian family. Dis Markers 2015:e828970CrossRef Syx D, Symoens S, Steyaert W, De Paepe A, Coucke PJ, Malfait F (2015) Ehlers-Danlos syndrome, hypermobility type, is linked to chromosome 8p22-8p21.1 in an extended Belgian family. Dis Markers 2015:e828970CrossRef
14.
Zurück zum Zitat Castori M, Camerota F, Celletti C, Danese C, Santilli V, Saraceni VM et al (2010) Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients. Am J Med Genet A. 152A(3):556–564PubMedCrossRef Castori M, Camerota F, Celletti C, Danese C, Santilli V, Saraceni VM et al (2010) Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients. Am J Med Genet A. 152A(3):556–564PubMedCrossRef
15.
Zurück zum Zitat Castori M, Dordoni C, Morlino S, Sperduti I, Ritelli M, Valiante M et al (2015) Spectrum of mucocutaneous manifestations in 277 patients with joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Am J Med Genet C Semin Med Genet. 169C(1):43–53PubMedCrossRef Castori M, Dordoni C, Morlino S, Sperduti I, Ritelli M, Valiante M et al (2015) Spectrum of mucocutaneous manifestations in 277 patients with joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Am J Med Genet C Semin Med Genet. 169C(1):43–53PubMedCrossRef
16.
Zurück zum Zitat Castori M, Morlino S, Celletti C, Ghibellini G, Bruschini M, Grammatico P et al (2013) Re-writing the natural history of pain and related symptoms in the joint hypermobility syndrome/Ehlers–Danlos syndrome, hypermobility type. Am J Med Genet A. 161(12):2989–3004CrossRef Castori M, Morlino S, Celletti C, Ghibellini G, Bruschini M, Grammatico P et al (2013) Re-writing the natural history of pain and related symptoms in the joint hypermobility syndrome/Ehlers–Danlos syndrome, hypermobility type. Am J Med Genet A. 161(12):2989–3004CrossRef
17.
Zurück zum Zitat Castori M, Sperduti I, Celletti C, Camerota F, Grammatico P (2011) Symptom and joint mobility progression in the joint hypermobility syndrome (Ehlers-Danlos syndrome, hypermobility type). Clin Exp Rheumatol. 29(6):998–1005PubMed Castori M, Sperduti I, Celletti C, Camerota F, Grammatico P (2011) Symptom and joint mobility progression in the joint hypermobility syndrome (Ehlers-Danlos syndrome, hypermobility type). Clin Exp Rheumatol. 29(6):998–1005PubMed
18.
Zurück zum Zitat Castori M, Celletti C, Camerota F, Grammatico P (2011) Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome. Clin Exp Rheumatol. 29(3):597–598PubMed Castori M, Celletti C, Camerota F, Grammatico P (2011) Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome. Clin Exp Rheumatol. 29(3):597–598PubMed
19.
Zurück zum Zitat Maeland S, Assmus J, Berglund B (2011) Subjective health complaints in individuals with Ehlers-Danlos syndrome: a questionnaire study. Int J Nurs Stud. 48(6):720–724PubMedCrossRef Maeland S, Assmus J, Berglund B (2011) Subjective health complaints in individuals with Ehlers-Danlos syndrome: a questionnaire study. Int J Nurs Stud. 48(6):720–724PubMedCrossRef
20.
Zurück zum Zitat Fikree A, Chelimsky G, Collins H, Kovacic K, Aziz Q (2017) Gastrointestinal involvement in the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):181–187PubMedCrossRef Fikree A, Chelimsky G, Collins H, Kovacic K, Aziz Q (2017) Gastrointestinal involvement in the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):181–187PubMedCrossRef
21.
Zurück zum Zitat Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A (2017) A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 175(1):148–157PubMedCrossRef Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A (2017) A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 175(1):148–157PubMedCrossRef
23.
Zurück zum Zitat Juul-Kristensen B, Schmedling K, Rombaut L, Lurd H, Engelbert RHH (2017) Measurement properties of clinical assessment methods for classifying generalized joint hypermobility—a systematic review. Am J Med Genet C Semin Med Genet. 175(1):116–147PubMedCrossRef Juul-Kristensen B, Schmedling K, Rombaut L, Lurd H, Engelbert RHH (2017) Measurement properties of clinical assessment methods for classifying generalized joint hypermobility—a systematic review. Am J Med Genet C Semin Med Genet. 175(1):116–147PubMedCrossRef
24.
Zurück zum Zitat Hakim AJ, Grahame R (2003) A simple questionnaire to detect hypermobility: an adjunct to the assessment of patients with diffuse musculoskeletal pain. Int J Clin Pract. 57(3):163–166PubMedCrossRef Hakim AJ, Grahame R (2003) A simple questionnaire to detect hypermobility: an adjunct to the assessment of patients with diffuse musculoskeletal pain. Int J Clin Pract. 57(3):163–166PubMedCrossRef
25.
Zurück zum Zitat Chopra P, Tinkle B, Hamonet C, Brock I, Gompel A, Bulbena A et al (2017) Pain management in the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):212–219PubMedCrossRef Chopra P, Tinkle B, Hamonet C, Brock I, Gompel A, Bulbena A et al (2017) Pain management in the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):212–219PubMedCrossRef
26.
Zurück zum Zitat Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P (2017) Chronic fatigue in Ehlers–Danlos syndrome—hypermobile type. Am J Med Genet C Semin Med Genet. 175(1):168–174PubMedCrossRef Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P (2017) Chronic fatigue in Ehlers–Danlos syndrome—hypermobile type. Am J Med Genet C Semin Med Genet. 175(1):168–174PubMedCrossRef
27.
Zurück zum Zitat Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P (2017) Cardiovascular autonomic dysfunction in Ehlers–Danlos syndrome—hypermobile type. Am J Med Genet C Semin Med Genet. 175(1):168–174PubMedCrossRef Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P (2017) Cardiovascular autonomic dysfunction in Ehlers–Danlos syndrome—hypermobile type. Am J Med Genet C Semin Med Genet. 175(1):168–174PubMedCrossRef
28.
Zurück zum Zitat Bathen T, Hångmann AB, Hoff M, Andersen LØ, Rand-Hendriksen S (2013) Multidisciplinary treatment of disability in Ehlers-Danlos syndrome hypermobility type/hypermobility syndrome: a pilot study using a combination of physical and cognitive-behavioral therapy on 12 women. Am J Med Genet A. 161A(12):3005–3011PubMedCrossRef Bathen T, Hångmann AB, Hoff M, Andersen LØ, Rand-Hendriksen S (2013) Multidisciplinary treatment of disability in Ehlers-Danlos syndrome hypermobility type/hypermobility syndrome: a pilot study using a combination of physical and cognitive-behavioral therapy on 12 women. Am J Med Genet A. 161A(12):3005–3011PubMedCrossRef
29.
Zurück zum Zitat Raj SR (2006) The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 6(2):84–99PubMedPubMedCentral Raj SR (2006) The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 6(2):84–99PubMedPubMedCentral
30.
Zurück zum Zitat Schondorf R, Low PA (1993) Idiopathic postural orthostatic tachycardia syndrome. Neurology 43(1 Part 1):132–137PubMedCrossRef Schondorf R, Low PA (1993) Idiopathic postural orthostatic tachycardia syndrome. Neurology 43(1 Part 1):132–137PubMedCrossRef
31.
Zurück zum Zitat Wooley CF (1976) Where are the diseases of yesteryear? DaCosta’s syndrome, soldiers heart, the effort syndrome, neurocirculatory asthenia--and the mitral valve prolapse syndrome. Circulation. 53(5):749–751PubMedCrossRef Wooley CF (1976) Where are the diseases of yesteryear? DaCosta’s syndrome, soldiers heart, the effort syndrome, neurocirculatory asthenia--and the mitral valve prolapse syndrome. Circulation. 53(5):749–751PubMedCrossRef
33.
Zurück zum Zitat Robertson D (1999) The epidemic of orthostatic tachycardia and orthostatic hypotension. Am J Med Sci. 319:75–77CrossRef Robertson D (1999) The epidemic of orthostatic tachycardia and orthostatic hypotension. Am J Med Sci. 319:75–77CrossRef
34.
Zurück zum Zitat Goldstein DS, Robertson D, Esler M, Straus SE, Eisenhofer G (2002) Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med. 137(9):753–763PubMedCrossRef Goldstein DS, Robertson D, Esler M, Straus SE, Eisenhofer G (2002) Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med. 137(9):753–763PubMedCrossRef
35.
Zurück zum Zitat Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. Auton Neurosci. 2018;S1566–0702(18):30025–0. Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. Auton Neurosci. 2018;S1566–0702(18):30025–0.
36.
Zurück zum Zitat Garland EM, Raj SR, Black BK, Harris PA, Robertson D (2007) The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology. 69:790–798PubMedCrossRef Garland EM, Raj SR, Black BK, Harris PA, Robertson D (2007) The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology. 69:790–798PubMedCrossRef
37.
Zurück zum Zitat Thieben M, Sandroni P, Sletten D, Benrud-Larson L, Fealey R, Vernino S et al (2007) Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc. 82(3):308–313PubMedCrossRef Thieben M, Sandroni P, Sletten D, Benrud-Larson L, Fealey R, Vernino S et al (2007) Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc. 82(3):308–313PubMedCrossRef
38.
Zurück zum Zitat Arnold AC, Ng J, Raj SR (2018) Postural tachycardia syndrome – diagnosis, physiology, and prognosis. Auton Neurosci. S1566–0702(17):30354–30355 Arnold AC, Ng J, Raj SR (2018) Postural tachycardia syndrome – diagnosis, physiology, and prognosis. Auton Neurosci. S1566–0702(17):30354–30355
39.
Zurück zum Zitat Smith JJ, Porth CM, Erickson M (1994) Hemodynamic response to the upright posture. J Clin Pharmacol. 34(5):375–386PubMedCrossRef Smith JJ, Porth CM, Erickson M (1994) Hemodynamic response to the upright posture. J Clin Pharmacol. 34(5):375–386PubMedCrossRef
41.
Zurück zum Zitat Bonyhay I, Freeman R (2004) Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome. Circulation. 110(20):3193–3198PubMedCrossRef Bonyhay I, Freeman R (2004) Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome. Circulation. 110(20):3193–3198PubMedCrossRef
42.
Zurück zum Zitat Haensch C, Tosch M, Katona I, Weis J, Isenmann S (2014) Small-fiber neuropathy with cardiac denervation in postural tachycardia syndrome. Muscle Nerve. 50(6):956–961PubMedCrossRef Haensch C, Tosch M, Katona I, Weis J, Isenmann S (2014) Small-fiber neuropathy with cardiac denervation in postural tachycardia syndrome. Muscle Nerve. 50(6):956–961PubMedCrossRef
43.
Zurück zum Zitat Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M et al (2000) The neuropathic postural tachycardia syndrome. N Eng J Med. 343(14):1008–1014 Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M et al (2000) The neuropathic postural tachycardia syndrome. N Eng J Med. 343(14):1008–1014
44.
Zurück zum Zitat Sheldon R, Grubb B, Olshansky B, Shen W, Calkins H, Brignole M et al (2015) 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 12(6):e63CrossRef Sheldon R, Grubb B, Olshansky B, Shen W, Calkins H, Brignole M et al (2015) 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 12(6):e63CrossRef
45.
Zurück zum Zitat Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I et al (2000) Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 342(8):541–549PubMedCrossRef Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I et al (2000) Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 342(8):541–549PubMedCrossRef
46.
Zurück zum Zitat Robertson D, Flattem N, Tellioglu T, Carson R, Garland E, Shannon JR et al (2001) Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann N Y Acad Sci. 940:527–543PubMedCrossRef Robertson D, Flattem N, Tellioglu T, Carson R, Garland E, Shannon JR et al (2001) Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann N Y Acad Sci. 940:527–543PubMedCrossRef
47.
Zurück zum Zitat Marques FZ, Eikelis N, Bayles RG, Lambert EA, Straznicky NE, Hering D et al (2017) A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism. Mol Psychiatry. 22(1):134–141PubMedCrossRef Marques FZ, Eikelis N, Bayles RG, Lambert EA, Straznicky NE, Hering D et al (2017) A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism. Mol Psychiatry. 22(1):134–141PubMedCrossRef
48.
Zurück zum Zitat Bayles R, Harikrishnan KN, Lambert E, Baker EK, Agrotis A, Guo L et al (2012) Epigenetic modification of the norepinephrine transporter gene in postural tachycardia syndrome. Arterioscler Thromb Vasc Biol. 32(8):1910–1916PubMedCrossRef Bayles R, Harikrishnan KN, Lambert E, Baker EK, Agrotis A, Guo L et al (2012) Epigenetic modification of the norepinephrine transporter gene in postural tachycardia syndrome. Arterioscler Thromb Vasc Biol. 32(8):1910–1916PubMedCrossRef
49.
Zurück zum Zitat Lambert E, Eikelis N, Esler M, Dawood T, Schlaich M, Bayles R et al (2008) Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ Arrhythm Electrophysiol. 1(2):103–109PubMedCrossRef Lambert E, Eikelis N, Esler M, Dawood T, Schlaich M, Bayles R et al (2008) Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ Arrhythm Electrophysiol. 1(2):103–109PubMedCrossRef
50.
Zurück zum Zitat Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I et al (2002) Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 105(3):347–353PubMedCrossRef Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I et al (2002) Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 105(3):347–353PubMedCrossRef
51.
Zurück zum Zitat Green EA, Raj V, Shibao CA, Biaggioni I, Black BK, Dupont WD et al (2013) Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome. J Am Heart Assoc. 2(5):e000395PubMedPubMedCentralCrossRef Green EA, Raj V, Shibao CA, Biaggioni I, Black BK, Dupont WD et al (2013) Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome. J Am Heart Assoc. 2(5):e000395PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne DW et al (2005) Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 111(13):1574–1582PubMedCrossRef Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne DW et al (2005) Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 111(13):1574–1582PubMedCrossRef
53.
Zurück zum Zitat Parsaik A, Allison TG, Singer W, Sletten DM, Joyner MJ, Benarroch EE et al (2012) Deconditioning in patients with orthostatic intolerance. Neurology. 79(14):1435–1439PubMedPubMedCentralCrossRef Parsaik A, Allison TG, Singer W, Sletten DM, Joyner MJ, Benarroch EE et al (2012) Deconditioning in patients with orthostatic intolerance. Neurology. 79(14):1435–1439PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Nagiub M, Moskowitz W, Fortunato J (2018) Systematic literature review of pathophysiology of postural orthostatic tachycardia syndrome (angiotensin II receptor subtypes imbalance theory). Prog Pediatr Cardiol Nagiub M, Moskowitz W, Fortunato J (2018) Systematic literature review of pathophysiology of postural orthostatic tachycardia syndrome (angiotensin II receptor subtypes imbalance theory). Prog Pediatr Cardiol
55.
Zurück zum Zitat Sandroni P, Opfer-Gehrking TL, McPhee BR, Low PA (1999) Postural tachycardia syndrome: clinical features and follow-up study. Mayo Clin Proc. 74(11):1106–1110PubMedCrossRef Sandroni P, Opfer-Gehrking TL, McPhee BR, Low PA (1999) Postural tachycardia syndrome: clinical features and follow-up study. Mayo Clin Proc. 74(11):1106–1110PubMedCrossRef
56.
Zurück zum Zitat Goodman B (2018) Evaluation of postural tachycardia syndrome (POTS). Auton Neurosci 18(18):30015–30018 Goodman B (2018) Evaluation of postural tachycardia syndrome (POTS). Auton Neurosci 18(18):30015–30018
57.
Zurück zum Zitat Bagai K, Wakwe CI, Malow B, Black BK, Biaggioni I, Paranjape SY et al (2013) Estimation of sleep disturbances using wrist actigraphy in patients with postural tachycardia syndrome. Auton Neurosci. 177(2):260–265PubMedPubMedCentralCrossRef Bagai K, Wakwe CI, Malow B, Black BK, Biaggioni I, Paranjape SY et al (2013) Estimation of sleep disturbances using wrist actigraphy in patients with postural tachycardia syndrome. Auton Neurosci. 177(2):260–265PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD (2011) Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 58(2):167–175PubMedCrossRef Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD (2011) Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 58(2):167–175PubMedCrossRef
60.
Zurück zum Zitat Fu Q, Vangundy TB, Galbreath MM, Shibata S, Jain M, Hastings JL et al (2010) Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 55(25):2858–2868PubMedPubMedCentralCrossRef Fu Q, Vangundy TB, Galbreath MM, Shibata S, Jain M, Hastings JL et al (2010) Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 55(25):2858–2868PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Winker R, Barth A, Bidmon D, Ponocny I, Weber M, Mayr O et al (2005) Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension. 45(3):391–398PubMedCrossRef Winker R, Barth A, Bidmon D, Ponocny I, Weber M, Mayr O et al (2005) Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension. 45(3):391–398PubMedCrossRef
62.
Zurück zum Zitat Sousa A, Lebreiro A, Freitas J, Maciel MJ (2012) Long-term follow-up of patients with postural tachycardia syndrome. Clin Auton Res. 22(3):151–153PubMedCrossRef Sousa A, Lebreiro A, Freitas J, Maciel MJ (2012) Long-term follow-up of patients with postural tachycardia syndrome. Clin Auton Res. 22(3):151–153PubMedCrossRef
63.
Zurück zum Zitat Lai CC, Fischer PR, Brands CK, Fisher JL, Porter CJ, Driscoll SW et al (2009) Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and beta-blockers. Pacing Clin Electrophysiol. 32(2):234–238PubMedCrossRef Lai CC, Fischer PR, Brands CK, Fisher JL, Porter CJ, Driscoll SW et al (2009) Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and beta-blockers. Pacing Clin Electrophysiol. 32(2):234–238PubMedCrossRef
64.
Zurück zum Zitat Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P et al (2012) A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc. 87(8):746–752PubMedPubMedCentralCrossRef Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P et al (2012) A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc. 87(8):746–752PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Afrin LB (2013) Presentation, diagnosis, and management of mast cell activation syndrome. In: Murray DB (ed) Mast cells: phenotypic features, biological functions and role in immunity. Nova Science Publishers, Inc, pp 155–232 Afrin LB (2013) Presentation, diagnosis, and management of mast cell activation syndrome. In: Murray DB (ed) Mast cells: phenotypic features, biological functions and role in immunity. Nova Science Publishers, Inc, pp 155–232
66.
Zurück zum Zitat Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67(6):345–368PubMedCrossRef Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67(6):345–368PubMedCrossRef
67.
Zurück zum Zitat Metcalfe DD (1991) Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 96(3 Suppl):65S Metcalfe DD (1991) Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 96(3 Suppl):65S
68.
Zurück zum Zitat Roberts LJ, Oates JA (1991) Biochemical diagnosis of systemic mast cell disorders. J Invest Dermatol. 96(3 Suppl):65S Roberts LJ, Oates JA (1991) Biochemical diagnosis of systemic mast cell disorders. J Invest Dermatol. 96(3 Suppl):65S
69.
Zurück zum Zitat Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 37(6):435–453PubMedCrossRef Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 37(6):435–453PubMedCrossRef
70.
Zurück zum Zitat Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 25(7):603–625PubMedCrossRef Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 25(7):603–625PubMedCrossRef
71.
Zurück zum Zitat Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR et al (2007) Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. IAA. 142(2):158–164 Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR et al (2007) Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. IAA. 142(2):158–164
72.
Zurück zum Zitat Akin C, Valent P, Metcalfe DD (2010) Mast cell activation syndrome: proposed diagnostic criteria: towards a global classification for mast cell disorders. J Allergy Clin Immunol. 126(6):1099–1104PubMedPubMedCentralCrossRef Akin C, Valent P, Metcalfe DD (2010) Mast cell activation syndrome: proposed diagnostic criteria: towards a global classification for mast cell disorders. J Allergy Clin Immunol. 126(6):1099–1104PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC et al (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157(3):215PubMedCrossRef Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC et al (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157(3):215PubMedCrossRef
74.
Zurück zum Zitat Valent P, Akin C, Metcalfe DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 129(11):1420–1427PubMedPubMedCentralCrossRef Valent P, Akin C, Metcalfe DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 129(11):1420–1427PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Brockow K (2014) Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin N Am. 34(2):283–295CrossRef Brockow K (2014) Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin N Am. 34(2):283–295CrossRef
76.
Zurück zum Zitat Kettelhut BV, Metcalfe DD (1991) Pediatric mastocytosis. J Invest Dermatol. 96(3 Suppl):65S Kettelhut BV, Metcalfe DD (1991) Pediatric mastocytosis. J Invest Dermatol. 96(3 Suppl):65S
77.
Zurück zum Zitat Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS et al (1995) The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 96(6):2702–2710PubMedPubMedCentralCrossRef Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS et al (1995) The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 96(6):2702–2710PubMedPubMedCentralCrossRef
78.
Zurück zum Zitat Dahlin JS, Hallgren J (2015) Mast cell progenitors: origin, development and migration to tissues. Mol Immunol. 63(1):9–17PubMedCrossRef Dahlin JS, Hallgren J (2015) Mast cell progenitors: origin, development and migration to tissues. Mol Immunol. 63(1):9–17PubMedCrossRef
79.
Zurück zum Zitat Silva EZ (2014) Marcelino da, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 62(10):698–738PubMedCrossRef Silva EZ (2014) Marcelino da, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 62(10):698–738PubMedCrossRef
80.
81.
Zurück zum Zitat Molderings GJ, Brettner S, Homann J, Afrin LB (2011) Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 4(1):10PubMedPubMedCentralCrossRef Molderings GJ, Brettner S, Homann J, Afrin LB (2011) Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 4(1):10PubMedPubMedCentralCrossRef
82.
Zurück zum Zitat Valent P (2013) Mast cell activation syndromes: definition and classification. Eur J Allergy Clin Immunol 68:417–424CrossRef Valent P (2013) Mast cell activation syndromes: definition and classification. Eur J Allergy Clin Immunol 68:417–424CrossRef
83.
Zurück zum Zitat Cardet J, Castells M, Hamilton M (2013) Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep. 13(1):10–18PubMedPubMedCentralCrossRef Cardet J, Castells M, Hamilton M (2013) Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep. 13(1):10–18PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Seneviratne S, Maitland A, Afrin L (2017) Mast cell disorders in Ehlers–Danlos syndrome. Am J Med Genet C Semin Med Genet. 175C(1):226–236CrossRef Seneviratne S, Maitland A, Afrin L (2017) Mast cell disorders in Ehlers–Danlos syndrome. Am J Med Genet C Semin Med Genet. 175C(1):226–236CrossRef
85.
Zurück zum Zitat Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL et al (2016) Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg’s Arch Pharmacol 389:671CrossRef Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL et al (2016) Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg’s Arch Pharmacol 389:671CrossRef
86.
Zurück zum Zitat Sokol KC, Ghazi A, Kelly BC, Grant JA (2014) Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2(3):266–270PubMedCrossRef Sokol KC, Ghazi A, Kelly BC, Grant JA (2014) Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2(3):266–270PubMedCrossRef
87.
Zurück zum Zitat Garriga MM, Friedman MM, Metcalfe DD (1988) A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol. 82(3 Pt 1):425–432PubMedCrossRef Garriga MM, Friedman MM, Metcalfe DD (1988) A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol. 82(3 Pt 1):425–432PubMedCrossRef
88.
Zurück zum Zitat Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P et al (2007) Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood. 110(7):2331–2333PubMedPubMedCentralCrossRef Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P et al (2007) Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood. 110(7):2331–2333PubMedPubMedCentralCrossRef
89.
Zurück zum Zitat Astle JM, Rose MG, Racke FK, Tormey CA, Siddon AJ (2017) R634W KIT mutation in an adult with systemic mastocytosis. Lab Med. 48(3):253–257PubMedCrossRef Astle JM, Rose MG, Racke FK, Tormey CA, Siddon AJ (2017) R634W KIT mutation in an adult with systemic mastocytosis. Lab Med. 48(3):253–257PubMedCrossRef
90.
Zurück zum Zitat Pollard WL, Beachkofsky TM, Kobayashi TT (2015) Novel R634W c-kit mutation identified in familial mastocytosis. Pediatr Dermatol. 32(2):267–270PubMedCrossRef Pollard WL, Beachkofsky TM, Kobayashi TT (2015) Novel R634W c-kit mutation identified in familial mastocytosis. Pediatr Dermatol. 32(2):267–270PubMedCrossRef
91.
Zurück zum Zitat Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 103(8):3222–3225PubMedCrossRef Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 103(8):3222–3225PubMedCrossRef
92.
Zurück zum Zitat Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A et al (2003) One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 162(3):737–746PubMedPubMedCentralCrossRef Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A et al (2003) One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 162(3):737–746PubMedPubMedCentralCrossRef
93.
Zurück zum Zitat Grahame R, Bird HA, Child A (2000) The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol. 27(7):1777–1779PubMed Grahame R, Bird HA, Child A (2000) The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol. 27(7):1777–1779PubMed
94.
Zurück zum Zitat Tinkle BT, Bird HA, Grahame R, Lavallee M, Levy HP, Sillence D (2009) The lack of clinical distinction between the hypermobility type of Ehlers-Danlos syndrome and the joint hypermobility syndrome (a.k.a. hypermobility syndrome). Am J Med Genet A. 149A(11):2368–2370PubMedCrossRef Tinkle BT, Bird HA, Grahame R, Lavallee M, Levy HP, Sillence D (2009) The lack of clinical distinction between the hypermobility type of Ehlers-Danlos syndrome and the joint hypermobility syndrome (a.k.a. hypermobility syndrome). Am J Med Genet A. 149A(11):2368–2370PubMedCrossRef
95.
Zurück zum Zitat Castori M, Dordoni C, Valiante M, Sperduti I, Ritelli M, Morlino S et al (2014) Nosology and inheritance pattern(s) of joint hypermobility syndrome and Ehlers-Danlos syndrome, hypermobility type: a study of intrafamilial and interfamilial variability in 23 Italian pedigrees. Am J Med Genet A. 164(12):3010–3020CrossRef Castori M, Dordoni C, Valiante M, Sperduti I, Ritelli M, Morlino S et al (2014) Nosology and inheritance pattern(s) of joint hypermobility syndrome and Ehlers-Danlos syndrome, hypermobility type: a study of intrafamilial and interfamilial variability in 23 Italian pedigrees. Am J Med Genet A. 164(12):3010–3020CrossRef
96.
Zurück zum Zitat Rowe P, Barron D, Calkins H, Maumenee I, Tong PY, Geraghty MT (1999) Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr. 135(4):494–499PubMedCrossRef Rowe P, Barron D, Calkins H, Maumenee I, Tong PY, Geraghty MT (1999) Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr. 135(4):494–499PubMedCrossRef
97.
Zurück zum Zitat Grigoriou E, Boris JR, Dormans JP (2015) Postural Orthostatic Tachycardia Syndrome (POTS): association with Ehlers-Danlos syndrome and orthopaedic considerations. Clin Orthop Relat Res 473(2):722PubMedCrossRef Grigoriou E, Boris JR, Dormans JP (2015) Postural Orthostatic Tachycardia Syndrome (POTS): association with Ehlers-Danlos syndrome and orthopaedic considerations. Clin Orthop Relat Res 473(2):722PubMedCrossRef
98.
Zurück zum Zitat Wallman D, Weinberg J, Hohler AD. Ehlers–Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurol Sci. 2014;340(1–2):99–102. Wallman D, Weinberg J, Hohler AD. Ehlers–Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurol Sci. 2014;340(1–2):99–102.
99.
Zurück zum Zitat Gazit Y, Nahir AM, Grahame R, Jacob G (2003) Dysautonomia in the joint hypermobility syndrome. Am J Med. 115(1):33–40PubMedCrossRef Gazit Y, Nahir AM, Grahame R, Jacob G (2003) Dysautonomia in the joint hypermobility syndrome. Am J Med. 115(1):33–40PubMedCrossRef
100.
Zurück zum Zitat Miglis M, Schultz B, Muppidi S (2017) Postural tachycardia in hypermobile Ehlers-Danlos syndrome: a distinct subtype? Auton Neurosci. 208:146–149PubMedCrossRef Miglis M, Schultz B, Muppidi S (2017) Postural tachycardia in hypermobile Ehlers-Danlos syndrome: a distinct subtype? Auton Neurosci. 208:146–149PubMedCrossRef
101.
Zurück zum Zitat Shibao C, Jackson Roberts IIL, Raj S, Black B, Harris P, Biaggioni I (2005) Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 45(3):385–390PubMedCrossRef Shibao C, Jackson Roberts IIL, Raj S, Black B, Harris P, Biaggioni I (2005) Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 45(3):385–390PubMedCrossRef
102.
Zurück zum Zitat Doherty T, White A (2018) Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. S1566–0702(17):30338–30337 Doherty T, White A (2018) Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. S1566–0702(17):30338–30337
103.
Zurück zum Zitat Cheung I, Vadas P (2015) A new disease cluster: mast cell activation syndrome, postural orthostatic tachycardia syndrome, and Ehlers-Danlos syndrome. J Allergy Clin Immunol. 135(2):AB65CrossRef Cheung I, Vadas P (2015) A new disease cluster: mast cell activation syndrome, postural orthostatic tachycardia syndrome, and Ehlers-Danlos syndrome. J Allergy Clin Immunol. 135(2):AB65CrossRef
104.
Zurück zum Zitat Vengoechea J (2018) In reply to “Mast Cell Disorders in Ehlers-Danlos Syndrome”. Am J Med Genet. 176(1):250PubMedCrossRef Vengoechea J (2018) In reply to “Mast Cell Disorders in Ehlers-Danlos Syndrome”. Am J Med Genet. 176(1):250PubMedCrossRef
105.
Zurück zum Zitat Beighton P, Grahame R, Bird H (2012) The molecular basis of joint hypermobility. In: Hypermobility of joints. Springer, pp 27–47 Beighton P, Grahame R, Bird H (2012) The molecular basis of joint hypermobility. In: Hypermobility of joints. Springer, pp 27–47
106.
Zurück zum Zitat Zweers MC, Hakim AJ, Grahame R, Schalkwijk J (2004) Joint hypermobility syndromes: the pathophysiologic role of tenascin-X gene defects. Arthritis Rheum. 50(9):2742–2749PubMedCrossRef Zweers MC, Hakim AJ, Grahame R, Schalkwijk J (2004) Joint hypermobility syndromes: the pathophysiologic role of tenascin-X gene defects. Arthritis Rheum. 50(9):2742–2749PubMedCrossRef
107.
Zurück zum Zitat Hirai S, Ohyane C, Kim Y, Lin S, Goto T, Takahashi N et al (2014) Involvement of mast cells in adipose tissue fibrosis. Am J Physiol Endocrinol Metab. 306(3):247CrossRef Hirai S, Ohyane C, Kim Y, Lin S, Goto T, Takahashi N et al (2014) Involvement of mast cells in adipose tissue fibrosis. Am J Physiol Endocrinol Metab. 306(3):247CrossRef
108.
Zurück zum Zitat Hügle T (2014) Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly. 144:w13999PubMed Hügle T (2014) Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly. 144:w13999PubMed
109.
Zurück zum Zitat Bradding P, Pejler G (2018) The controversial role of mast cells in fibrosis. Immunol Rev. 282(1):198–231PubMedCrossRef Bradding P, Pejler G (2018) The controversial role of mast cells in fibrosis. Immunol Rev. 282(1):198–231PubMedCrossRef
110.
Zurück zum Zitat Cairns JA, Walls AF (1997) Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest. 99(6):1313–1321PubMedPubMedCentralCrossRef Cairns JA, Walls AF (1997) Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest. 99(6):1313–1321PubMedPubMedCentralCrossRef
111.
Zurück zum Zitat Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart F et al (2002) Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy. 32(2):237–246PubMedCrossRef Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart F et al (2002) Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy. 32(2):237–246PubMedCrossRef
112.
Zurück zum Zitat Manel J, Befus D, Newhouse M, Bienenstock J, Gauldie J, McMaster U (1988) Effect of histamine on proliferation of normal human adult lung fibroblasts. Thorax. 43(7):552–558CrossRef Manel J, Befus D, Newhouse M, Bienenstock J, Gauldie J, McMaster U (1988) Effect of histamine on proliferation of normal human adult lung fibroblasts. Thorax. 43(7):552–558CrossRef
113.
Zurück zum Zitat Hatamochi A, Fujiwara K, Ueki H (1985) Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch Dermatol Res. 277(1):60–64PubMedCrossRef Hatamochi A, Fujiwara K, Ueki H (1985) Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch Dermatol Res. 277(1):60–64PubMedCrossRef
114.
Zurück zum Zitat Russel JD, Russell SB, Trupin KM (1977) The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J Cell Physiol. 93(3):389–393PubMedCrossRef Russel JD, Russell SB, Trupin KM (1977) The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J Cell Physiol. 93(3):389–393PubMedCrossRef
115.
Zurück zum Zitat Abe M, Kurosawa M, Ishikawa O, Miyachi Y (2000) Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production. J Allergy Clin Immunol. 106(1 Pt 2):78CrossRef Abe M, Kurosawa M, Ishikawa O, Miyachi Y (2000) Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production. J Allergy Clin Immunol. 106(1 Pt 2):78CrossRef
116.
Zurück zum Zitat De Wandele I, Rombaut L, Leybaert L, Van de Borne P, De Backer T, Malfait F et al (2014) Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers–Danlos syndrome. Semin Arthritis Rheum. 44(1):93–100PubMedCrossRef De Wandele I, Rombaut L, Leybaert L, Van de Borne P, De Backer T, Malfait F et al (2014) Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers–Danlos syndrome. Semin Arthritis Rheum. 44(1):93–100PubMedCrossRef
117.
Zurück zum Zitat Bonamichi-Santos R, Yoshimi-Kanamori K, Giavina-Bianchi P, Aun MV (2018) Association of postural tachycardia syndrome and Ehlers-Danlos syndrome with mast cell activation disorders. Immunol Allergy Clin N Am 38(3):497–504CrossRef Bonamichi-Santos R, Yoshimi-Kanamori K, Giavina-Bianchi P, Aun MV (2018) Association of postural tachycardia syndrome and Ehlers-Danlos syndrome with mast cell activation disorders. Immunol Allergy Clin N Am 38(3):497–504CrossRef
118.
Zurück zum Zitat Sabato V, Van De Vijver E, Hagendorens M, Vrelust I, Reyniers E, Fransen E et al (2014) Familial hypertryptasemia with associated mast cell activation syndrome. J Allergy Clin Immunol 134(6):1450.e3CrossRef Sabato V, Van De Vijver E, Hagendorens M, Vrelust I, Reyniers E, Fransen E et al (2014) Familial hypertryptasemia with associated mast cell activation syndrome. J Allergy Clin Immunol 134(6):1450.e3CrossRef
119.
Zurück zum Zitat Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O’Brien M et al (2014) Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol. 133(5):1471–1474PubMedPubMedCentralCrossRef Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O’Brien M et al (2014) Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol. 133(5):1471–1474PubMedPubMedCentralCrossRef
120.
Zurück zum Zitat Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y et al (2016) Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 48(12):1564–1569PubMedPubMedCentralCrossRef Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y et al (2016) Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 48(12):1564–1569PubMedPubMedCentralCrossRef
121.
Zurück zum Zitat Cardamone C, Parente R, Feo GD, Triggiani M (2016) Mast cells as effector cells of innate immunity and regulators of adaptive immunity. Immunol Lett 178:10–14PubMedCrossRef Cardamone C, Parente R, Feo GD, Triggiani M (2016) Mast cells as effector cells of innate immunity and regulators of adaptive immunity. Immunol Lett 178:10–14PubMedCrossRef
122.
Zurück zum Zitat Galli SJ, Tsai M (2010) Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol. 40(7):1843–1851PubMedPubMedCentralCrossRef Galli SJ, Tsai M (2010) Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol. 40(7):1843–1851PubMedPubMedCentralCrossRef
123.
Zurück zum Zitat Suurmond J, Dorjée AL, Knol EF, Huizinga TWJ, Toes REM (2015) Differential TLR-induced cytokine production by human mast cells is amplified by FcɛRI triggering. Clin Exp Allergy. 45(4):788–796PubMedCrossRef Suurmond J, Dorjée AL, Knol EF, Huizinga TWJ, Toes REM (2015) Differential TLR-induced cytokine production by human mast cells is amplified by FcɛRI triggering. Clin Exp Allergy. 45(4):788–796PubMedCrossRef
124.
Zurück zum Zitat Gallenga CE, Pandolfi F, Caraffa A, Kritas SK, Ronconi G, Toniato E et al (2019) Interleukin-1 family cytokines and mast cells: activation and inhibition. J Biol Regul Homeost Agents 33(1):1–6PubMed Gallenga CE, Pandolfi F, Caraffa A, Kritas SK, Ronconi G, Toniato E et al (2019) Interleukin-1 family cytokines and mast cells: activation and inhibition. J Biol Regul Homeost Agents 33(1):1–6PubMed
125.
Zurück zum Zitat Yu Y, Blokhuis BR, Garssen J, Redegeld FA (2016) Non-IgE mediated mast cell activation. Eur J Pharmacol 778:33–43PubMedCrossRef Yu Y, Blokhuis BR, Garssen J, Redegeld FA (2016) Non-IgE mediated mast cell activation. Eur J Pharmacol 778:33–43PubMedCrossRef
126.
Zurück zum Zitat Jakate S, Demeo M, John R, Tobin M, Keshavarzian A (2006) Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med. 130(3):362–367PubMedCrossRef Jakate S, Demeo M, John R, Tobin M, Keshavarzian A (2006) Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med. 130(3):362–367PubMedCrossRef
127.
Zurück zum Zitat Hahn HP, Hornick JL (2007) Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol. 31(11):1669–1676PubMedCrossRef Hahn HP, Hornick JL (2007) Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol. 31(11):1669–1676PubMedCrossRef
128.
Zurück zum Zitat Sethi A, Jain D, Roland BC, Kinzel J, Gibson J, Schrader R et al (2015) Performing colonic mast cell counts in patients with chronic diarrhea of unknown etiology has limited diagnostic use. Arch Pathol Lab Med. 139(2):225–232PubMedCrossRef Sethi A, Jain D, Roland BC, Kinzel J, Gibson J, Schrader R et al (2015) Performing colonic mast cell counts in patients with chronic diarrhea of unknown etiology has limited diagnostic use. Arch Pathol Lab Med. 139(2):225–232PubMedCrossRef
129.
Zurück zum Zitat Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL (2014) A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 38(6):832–843PubMedPubMedCentralCrossRef Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL (2014) A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 38(6):832–843PubMedPubMedCentralCrossRef
130.
Zurück zum Zitat Obrenovich MEM (2018) Leaky gut, leaky brain? Microorganisms 6(4) Obrenovich MEM (2018) Leaky gut, leaky brain? Microorganisms 6(4)
Metadaten
Titel
The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS)
verfasst von
Alison Haley Kucharik
Christopher Chang
Publikationsdatum
02.07.2019
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 3/2020
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-019-08755-8

Weitere Artikel der Ausgabe 3/2020

Clinical Reviews in Allergy & Immunology 3/2020 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.